Rankings / Mood, Anxiety & Stress

Xanomeline-trospium (KarXT / Cobenfy)

Mood, Anxiety & Stress · M1/M4 muscarinic agonist + peripheral antagonist

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

cholinergicprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Xanomeline-trospium (KarXT / Cobenfy) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

Bristol Myers Squibb (acquired Karuna 2024).

Typical use: 50/20 mg twice daily, titrate up to 125/30 mg twice daily — Rx.

What this is

Bristol Myers Squibb (acquired Karuna 2024). First fundamentally new schizophrenia mechanism since clozapine (1989). Avoids dopamine D2 blockade entirely — sidesteps weight gain, EPS, prolactin elevation, and tardive dyskinesia. Active investigation in Alzheimer's psychosis, ADHD, BPD. Major clinical advance even though efficacy is comparable to atypicals.

Mechanism

Combination drug: xanomeline is a centrally acting M1/M4 muscarinic acetylcholine receptor agonist (developed in 1990s but shelved due to peripheral cholinergic side effects); trospium is a peripherally restricted muscarinic antagonist that blocks the GI/cardiac side effects without crossing the BBB — allowing the central effect to be tolerated; first novel mechanism for schizophrenia in 50+ years

Dose & route

50/20 mg twice daily, titrate up to 125/30 mg twice daily

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Xanomeline-trospium (KarXT / Cobenfy) work?
Read Off Label rates the evidence for Xanomeline-trospium (KarXT / Cobenfy) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Bristol Myers Squibb (acquired Karuna 2024).
Is Xanomeline-trospium (KarXT / Cobenfy) safe?
Xanomeline-trospium (KarXT / Cobenfy) has a med risk profile in published human data. Legal status: Rx (FDA-approved Sept 2024 for schizophrenia). This is not medical advice — see the disclaimer.
What is the typical dose for Xanomeline-trospium (KarXT / Cobenfy)?
50/20 mg twice daily, titrate up to 125/30 mg twice daily
How does Xanomeline-trospium (KarXT / Cobenfy) work?
Combination drug: xanomeline is a centrally acting M1/M4 muscarinic acetylcholine receptor agonist (developed in 1990s but shelved due to peripheral cholinergic side effects); trospium is a peripherally restricted muscarinic antagonist that blocks the GI/cardiac side effects without crossing the BBB — allowing the central effect to be tolerated; first novel mechanism for schizophrenia in 50+ years

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.